Compare Alphabet Inc Class A (GOOGL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs TG Therapeutics Inc — how do they compare? Alphabet Inc Class A trades at $344.88 (market cap $4.20T), while TG Therapeutics Inc trades at $49.52 (market cap $7.58B). The key difference: Alphabet Inc Class A is far larger — about 554.1× TG Therapeutics Inc's market cap, and Alphabet Inc Class A pays a 0.26% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| GOOGL | TGTX | |
|---|---|---|
Market Cap | $4.20T | $7.58B |
Sector | Media | Health |
52-Week High | $402.62 | $59.06 |
52-Week Low | $199.32 | $26.94 |
Enterprise Value | $4.08T | $7.78B |
Dividend Yield | 0.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $343.8, down 3.84% over 24 hours, with a bearish technical signal but strong fundamentals. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 highlight robust profit growth, with net income reaching $132.17 billion in 2025. The stock faces near-term pressure from technical indicators but benefits from AI-driven revenue expansion and a consensus analyst price target of $426.28, suggesting significant upside potential.
The outlook remains positive due to solid earnings performance and AI investments, though risks include antitrust scrutiny and market volatility. With 85% of analysts rating it a buy, GOOGL offers long-term growth opportunities, but investors should monitor competitive and regulatory challenges that could impact valuation.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
